Welcome To Campus Sanofi Thailand

Remission that holds after treatment stops is no longer a hypothetical. This edition opens with a review defining what disease modification in atopic dermatitis would actually require, then looks at what the evidence shows so far: sustained benefit in patients over 60, whether treating children early can change where the atopic march ends, and what happens to skin nerves and barrier proteins after 16 weeks of treatment.

Access ERS 2026 Congress highlights on severe asthma, COPD, and biologic therapies. Real-world evidence and clinical insights for HCPs

In this issue, we feature three studies that provide insights into disease modification in atopic dermatitis, examining microbiome restoration, long-term infection outcomes in real-world practice, and clinical responses in erythrodermic presentations.

We are pleased to share with you information on ‘Safety and Efficacy of Treatment with Dupilumab for up to 2 Years in Infants and Young Children with Atopic Dermatitis,’ together with the ‘Guidelines of Care for the Management of Atopic Dermatitis in Pediatric Patients.’ We believe these publications may be of interest to you.

This email highlights key evidence regarding dupilumab, including its long-term safety and efficacy profile in infants and young children with atopic dermatitis. It also presents current guideline recommendations, which strongly support the use of dupilumab in children aged 6 months and older with moderate-to-severe atopic dermatitis.